Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial

Journal:
The Lancet Oncology
Published:
DOI:
10.1016/s1470-2045(25)00559-5
Affiliations:
9
Authors:
26
Go to article
Institutions Authors Share
Peter MacCallum Cancer Centre (Peter Mac), Australia
15.166667
15.166667
 0.58
The University of Melbourne (UniMelb), Australia
10.833333
10.833333
 0.42
Interested in Biomedical Engineering?